share_log

Bellerophon Therapeutics Shares Are Trading Higher After the FDA Accepted the Company's Proposal to Reduce the Study Size for Its Ongoing Registrational REBUILD Phase 3 Trial of INOpulse for the Treatment of Fibrotic Interstitial Lung Disease.

Bellerophon Therapeutics Shares Are Trading Higher After the FDA Accepted the Company's Proposal to Reduce the Study Size for Its Ongoing Registrational REBUILD Phase 3 Trial of INOpulse for the Treatment of Fibrotic Interstitial Lung Disease.

在FDA接受了该公司正在进行的INOPulse治疗间质性肺疾病注册重建第三阶段试验的研究规模的建议后,Bellerophon治疗公司的股价上涨。
Benzinga ·  2022/09/27 15:31

Bellerophon Therapeutics shares are trading higher after the FDA accepted the company's proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial of INOpulse for the treatment of fibrotic Interstitial Lung Disease.

在FDA接受了该公司的提议,缩小其正在进行的INOPulse治疗纤维化间质性肺部疾病的注册重建第三阶段试验的研究规模后,Bellerophon治疗公司的股价上涨。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发